Department of Pediatrics, University of California, San Francisco, CA, USA.
Division of Pediatric Infectious Diseases and Global Health, University of California, San Francisco, CA, USA.
Nat Commun. 2022 Jul 30;13(1):4422. doi: 10.1038/s41467-022-32188-1.
Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination during pregnancy, and the levels of protection provided to their newborns through placental transfer of antibodies. Here, we evaluate the transplacental transfer of mRNA vaccine products and functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during late pregnancy. We find no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery. However, we find time-dependent efficient transfer of IgG and neutralizing antibodies to the neonate that persists during early infancy. Additionally, using phage immunoprecipitation sequencing, we find a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy. Timing of vaccination during pregnancy is critical to ensure transplacental transfer of protective antibodies during early infancy.
需要研究来评估 mRNA SARS-CoV-2 疫苗在妊娠期间的安全性和有效性，以及通过胎盘转移抗体为其新生儿提供的保护水平。在这里，我们评估了在 20 名妊娠晚期接种疫苗的个体中，mRNA 疫苗产品和功能性抗 SARS-CoV-2 抗体在妊娠和婴儿早期的胎盘转移情况。我们没有在分娩时的母血、胎盘组织或脐带血中发现 mRNA 疫苗产品的证据。然而，我们发现 IgG 和中和抗体能够有效地转移到新生儿体内，并在婴儿早期持续存在。此外，我们使用噬菌体免疫沉淀测序发现，SARS-CoV-2 Spike 蛋白表位结合的疫苗特异性特征在妊娠期间通过胎盘转移。妊娠期间接种疫苗的时间至关重要，以确保在婴儿早期通过胎盘转移保护性抗体。
